tiprankstipranks
Trending News
More News >
Apellis Pharmaceuticals (APLS)
:APLS
US Market
Advertisement

Apellis Pharmaceuticals (APLS) Ownership - Who Owns Apellis Pharmaceuticals?

Compare
959 Followers

Apellis Pharmaceuticals (APLS) Ownership Overview

3.26%19.86%44.10%16.29%16.48%
44.10% Other Institutional Investors
16.29% ETFs
16.48% Public Companies and
Individual Investors
The ownership structure of Apellis Pharmaceuticals (APLS) stock is a mix of institutional, retail, and individual investors. Approximately 80.25% of the company’s stock is owned by Institutional Investors, 3.26% is owned by Insiders, and 16.48% is owned by Public Companies and Individual Investors.
The ownership structure of Apellis Pharmaceuticals (APLS) stock is a mix of institutional, retail, and individual investors. Approximately 63.97% of the company’s stock is owned by Institutional Investors, 3.26% is owned by Insiders, and 16.29% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Sep 12, 2025
xxxxxxxxxxxxx
$523400
Sep 10, 2025
xxxxxxxxxxxxx
$278300
Sep 03, 2025
xxxxxxxxxxxxx
$15382
Aug 29, 2025
xxxxxxxxxxxxx
$6352743

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$158196
Jun 30, 2025
xxxxxxxxxxxxx
$745905
Jun 30, 2025
xxxxxxxxxxxxx
$9190277

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
9,286,573Institution7.35%226,499,515
9,171,002Institution7.26%223,680,739
8,998,873Institution7.13%219,482,512
5,129,036Institution4.06%125,097,188
2,798,183Institution2.22%68,247,683
1,844,720Institution1.46%44,992,721
1,646,027Insider1.30%40,146,599
1,160,496Insider0.92%28,304,497
1,089,564Institution0.86%26,574,466
1,055,763Institution0.84%25,750,060

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
9,286,573Institution7.35%226,499,515
9,171,002Institution7.26%223,680,739
1,089,564Institution0.86%26,574,466
1,055,763Institution0.84%25,750,060
686,301Institution0.54%16,738,881
467,487Institution0.37%11,402,008
426,594Institution0.34%10,404,628
408,263Institution0.32%9,957,535
397,869Institution0.32%9,704,025
315,120Institution0.25%7,685,777

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,361,043Institution2.66%75,085,701
2,591,601Institution2.05%57,896,366
1,818,247Institution1.44%45,183,438
1,465,988Institution1.16%32,750,172
1,158,795Institution0.92%25,887,480
804,762Institution0.64%17,053,241
804,762Institution0.64%17,053,241
804,762Institution0.64%17,053,241
804,762Institution0.64%17,053,241
718,192Institution0.57%17,516,703

FAQ

Who Owns Apellis Pharmaceuticals (APLS)?
According to the latest TipRanks data, approximately 44.10% of the company's stock is held by institutional investors, 3.26% is held by insiders, and 16.48% is held by retail investors.
    What percentage of Apellis Pharmaceuticals (APLS) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 44.10% of Apellis Pharmaceuticals (APLS) stock is held by institutional investors.
      What percentage of Apellis Pharmaceuticals (APLS) stock is held by retail investors?
      According to the latest TipRanks data, approximately 16.48% of Apellis Pharmaceuticals (APLS) stock is held by retail investors.
        Who owns the most shares of Apellis Pharmaceuticals (APLS)?
        VANGUARD SPECIALIZED FUNDS owns the most shares of Apellis Pharmaceuticals (APLS).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis